Refer an Adult Patient

UChicago Medicine is proud to offer all commercially available CAR T-cell therapy products. See below for products available by diagnosis:

Tecartus (brexucabtagene autoleucel)

  • Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Breyanzi (lisocabtagene maraleucel)

  • Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B

Kymriah (tisagenlecleucel)

  • Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma

Yescarta (axicabtagene ciloleucel)

  • Large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
  • Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Tecartus (brexucabtagene autoleucel)

  • Relapsed or refractory mantle cell lymphoma (MCL)

Abecma (idecabtagene vicleucel)

  • Relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody

Carvykti (ciltacabtagene autoleucel)

  • Relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
 

Find a CAR T-cell therapy clinical trial underway at UChicago Medicine

To refer a patient to our CAR T-cell therapy program, please call 1-844-482-7823.

 

Refer a Pediatric Patient

Kymriah (tisagenlecleucel) CAR T-cell therapy is available for patients with: 

  • Primary refractory B-cell pediatric acute lymphoblastic leukemia (ALL)
  • Relapsed or refractory B-cell ALL
  • Relapsed B-cell ALL

To refer a patient to our CAR T-cell therapy program, please call 1-844-482-7823.

Clinical Trials of New Cellular Therapies

Our physicians work to bring the latest breakthroughs in cellular therapy treatments quickly to their patients’ bedsides. Several new cellular therapies are now being tested through clinical trials for blood cancers and solid tumors.

Convenient Locations for Cancer Care